Not currently recruiting at University of California Health
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UC Irvine
- Dates
- study startedestimated completion
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Kite, A Gilead Company
- ID
- NCT05371093
- Phase
- Phase 3 Lymphoma Research Study
- Study Type
- Interventional
- Participants
- Expecting 230 study participants
- Last Updated